{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:01:33Z","timestamp":1792627293225,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The safety and efficacy of blinatumomab, a CD3\/CD19-directed bispecific molecule, were examined in an open-label, single-arm, expanded access study (RIALTO). Children (&amp;gt;28 days and &amp;lt;18 years) with CD19+ relapsed\/refractory B-cell precursor acute lymphoblastic leukemia (R\/R B-ALL) received up to 5 cycles of blinatumomab by continuous infusion (cycle: 4 weeks on\/2 weeks off). The primary end point was incidence of adverse events. Secondary end points included complete response (CR) and measurable residual disease (MRD) response within the first 2 cycles and relapse-free survival (RFS), overall survival (OS), and allogeneic hematopoietic stem cell transplant (alloHSCT) after treatment. At final data cutoff (10 January 2020), 110 patients were enrolled (median age, 8.5 years; 88% had \u22655% baseline blasts). A low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%) was reported; no blinatumomab-related fatal adverse events were recorded. The probability of response was not affected by the presence of cytogenetic\/molecular abnormalities. Median OS was 14.6 months (95% confidence interval [CI]: 11.0-not estimable) and was significantly better for MRD responders vs MRD nonresponders (not estimable vs 9.3; hazard ratio, 0.18; 95% CI: 0.08-0.39). Of patients achieving CR after 2 cycles, 73.5% (95% CI: 61.4%-83.5%) proceeded to alloHSCT. One-year OS probability was higher for patients who received alloHSCT vs without alloHSCT after blinatumomab (87% vs 29%). These findings support the use of blinatumomab as a safe and efficacious treatment of pediatric R\/R B-ALL. This trial was registered at www.clinicaltrials.gov as #NCT02187354.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005579","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T17:00:56Z","timestamp":1641229256000},"page":"1004-1014","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis"],"prefix":"10.1182","volume":"6","author":[{"given":"Franco","family":"Locatelli","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, IRCCS Bambino Ges\u00f9 Children's Hospital, Sapienza, University of Rome, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Mergen","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"additional","affiliation":[{"name":"Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Jeha","sequence":"additional","affiliation":[{"name":"Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Gerhardt","family":"Schlegel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Children's Hospital W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children's Research Centre, University Children's Hospital Z\u00fcrich, Z\u00fcrich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, University Children's Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Brethon","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Immunology Department, Robert-Debr\u00e9 Hospital, AP-HP, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"R\u00f6ssig","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, University Children's Hospital M\u00fcnster, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Kormany","sequence":"additional","affiliation":[{"name":"Global Patient Safety, Amgen Inc., Thousand Oaks, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Viswagnachar","sequence":"additional","affiliation":[{"name":"Biostatistical Sciences, IQVIA, Bangalore, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Chen-Santel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Oncology and Hematology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany; and"},{"name":"University Medical Center Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"issue":"16","key":"2022020416231802500_B1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med."},{"issue":"27","key":"2022020416231802500_B2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol."},{"issue":"14","key":"2022020416231802500_B3","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2022020416231802500_B4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022020416231802500_B5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1038\/leu.2012.123","article-title":"Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis","volume":"26","author":"Ruggeri","year":"2012","journal-title":"Leukemia."},{"issue":"5","key":"2022020416231802500_B6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa","year":"2018","journal-title":"Br J Haematol."},{"issue":"36","key":"2022020416231802500_B7","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2007.10.7508","article-title":"Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children\u2019s Oncology Group study CCG-1952","volume":"25","author":"Malempati","year":"2007","journal-title":"J Clin Oncol."},{"issue":"16","key":"2022020416231802500_B8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood."},{"issue":"14","key":"2022020416231802500_B9","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022020416231802500_B10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2022020416231802500_B11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"issue":"9","key":"2022020416231802500_B12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"issue":"36","key":"2022020416231802500_B13","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022020416231802500_B14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse b-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA."},{"issue":"9","key":"2022020416231802500_B15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA."},{"issue":"7","key":"2022020416231802500_B16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study [corrections published in Blood Cancer J. 2021;11:173 and Blood Cancer J. 2021;11:28]","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J."},{"issue":"6","key":"2022020416231802500_B17","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2018.210104","article-title":"Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation","volume":"104","author":"Mouttet","year":"2019","journal-title":"Haematologica."},{"issue":"7","key":"2022020416231802500_B18","doi-asserted-by":"crossref","first-page":"E455","DOI":"10.3390\/diagnostics10070455","article-title":"Integrated genomic analysis of chromosomal alterations and mutations in B-cell acute lymphoblastic leukemia reveals distinct genetic profiles at relapse","volume":"10","author":"Forero-Castro","year":"2020","journal-title":"Diagnostics (Basel)."},{"issue":"24","key":"2022020416231802500_B19","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","article-title":"Unrelated donor vs HLA-haploidentical \u03b1\/\u03b2 T-cell- and B-cell-depleted HSCT in children with acute leukemia","volume":"132","author":"Bertaina","year":"2018","journal-title":"Blood."},{"issue":"14","key":"2022020416231802500_B20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [correction published in Blood. 2019;133(24):2625]","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2022020416231802500_B21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin Pharmacol Ther."},{"issue":"26","key":"2022020416231802500_B22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"18","key":"2022020416231802500_B23","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med."},{"issue":"14","key":"2022020416231802500_B24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med."},{"issue":"10254","key":"2022020416231802500_B25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/1004\/1867731\/advancesadv2021005579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/1004\/1867731\/advancesadv2021005579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:57:41Z","timestamp":1643975861000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/3\/1004\/483306\/Blinatumomab-in-pediatric-relapsed-refractory-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005579","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}